CEMI News and Press, Chembio Diagnostics Inc. From 02/12/20

MEDFORD, N.Y., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced a $1.5 million purchase order from UNICEF for multiplex Zika tests and Micro Readers following the successfu...

LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Board of Directors has appointed diagnostics industry veteran John Sperz...

MEDFORD, N.Y., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced President and Chief Executive Officer John Sperzel has resigned for another opportunity. The Chembio Board o...

Chembio Diagnostics (NASDAQ: CEMI ) is up 15.8% after hours following its update on an FDA submission of its DPP HIV-Syphilis test. More news on: Chembio Diagnostics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

MEDFORD, N.Y., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today provided an update on its Premarket Approval application submission to the U.S. Food and Drug Administration (FDA) for...

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

MEDFORD, N.Y., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has completed its previously announced acquisition of Orangelife Comercio e Industria Ltda., a Brazi...

Chembio Diagnostics, Inc. (CEMI) Q3 2019 Earnings Conference Call November 07, 2019 4:30 AM ET Company Participants Philip Taylor - Investor Relations John Sperzel - President & Chief Executive Officer Neil Goldman - Executive Vice President & Chief Financial Officer C...

Chembio Diagnostics (NASDAQ: CEMI ): Q3 GAAP EPS of -$0.22 misses by $0.05 . More news on: Chembio Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...